Keeping Up Appearances | GenomeWeb

NEW YORK, Oct. 2 - To stay attractive to venture capital investors and remain competitive, young genomic companies must have a broad platform that reduces their failure rate, they must be able to generate drug candidates, and they should be more frugal, according to some industry watchers. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.